Biopharma Can Reduce the Cost of Bringing A Treatment to Market by More Than US$1 Billion, According to Accenture Report

NEW YORK; Oct. 26, 2021 – A new report from Accenture (NYSE: ACN) identifies three steps biopharmaceutical organizations could take to reduce the average cost of discovering and developing a treatment by more than US$1 billion. Furthermore, it could potentially create additional future revenue opportunities of up to US$450 million per treatment.

Comments

Popular posts from this blog

Add Custom Field in Output of Standard Report of ME2N

HANA Housekeeping using HANACleaner

Accenture to Strengthen Oracle Capabilities in the Middle East with AppsPro Acquisition